Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals
Provided are pharmaceutical compositions comprising a combination of 1-[2-[(4-fluorophenyl)(phenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-[bis(4-fluorophenyl)-methoxy]ethyl]-4-(3-phenylpropyl)piperazine (also known as vanoxerine). The pharmaceutical compositions can be useful for preventing or treating acute and/or chronic cardiac arrhythmias.
